Scientific Congresses in Hematology

Selected Data Presentations

Select "Upcoming" to see a list of future scientific congresses in hematology. Select "Past" to review data and presentations from recent congresses. This is not intended to be a comprehensive resource of all congresses and congress materials across therapeutic and disease areas.

Congress materials may include information about investigational use(s) of compounds/products that are not approved for use by the U.S. Food and Drug Administration (FDA) and/or are inconsistent with the Prescribing Information. Takeda does not recommend the use of any Takeda product beyond the approved labeling. Any decisions regarding the usage of a Takeda product beyond the approved labeling is left to the discretion of the healthcare professional. Takeda makes no representations about whether investigational compounds or unapproved uses will be approved by the FDA.

 

Upcoming & Past Conferences

  • Upcoming

  • Past

Academy of Managed Care Pharmacy Nexus (AMCP Nexus), 2024

October 14 - 17, 2024 | Link to Event

Annual event with more than 2,500 members and non-members of the AMCP to engage on the latest innovations and most intentional networking in managed care pharmacy.

American Thrombosis and Hemostasis Network Data Summit (ATHN Data Summit), 2024

October 22 - 23, 2024 | Link to Event

Annual meeting discussing important research areas of hemophilia, health equity, thrombosis, Von Willebrand disease, rare blood disorders, and data management.

American Society of Hematology (ASH), 2024

December 7 - 12, 2024 | Link to Event

The premier global congress from the world's largest professional society serving both clinicians and scientists working in malignant and classical hematology.

Bleeding Disorders Conference (BDC), 2024

September 12 - 14, 2024

The National Bleeding Disorders Foundation (formally NHF)’s Annual Bleeding Disorders Conference brings the bleeding disorders community together for educational sessions, networking opportunities, and exhibits.

International Society on Thrombosis and Haemostasis (ISTH), 2024

June 22 - 26, 2024

Global congress featuring the world’s leading experts on thrombosis, hemostasis and vascular biology presenting the most recent advances, the latest science, and the newest clinical applications designed to improve patient care.

  • Global Prevalence of Anticoagulant Reversal for Major Bleeding and Urgent Surgery in Patients with Atrial Fibrillation and Venous Thromboembolism: A Systematic Review of Data from 38 Countries

Adynovate® [Antihemophilic Factor (Recombinant), PEGylated] & Advate® [Antihemophilic Factor (Recombinant)] & "other FVIII replacement therapies"

  • Physical Activity Engagement and Health-Related Quality Of Life in Patients with Hemophilia A Receiving Either Octocog Alfa Or Rurioctocog Alfa Pegol Versus Other FVIII Replacement Therapies
  • Clinical Outcomes in Patients with Hemophilia A Receiving Octocog Alfa or Rurioctocog Alfa Pegol Versus Other FVIII Replacement Therapies: Insights From The Ahead, CHESS II, and CHESS PAEDS Studies
  • The Impact of Recombinant Factor VIII Products on Inhibitor Development in Previously Untreated and Previously Treated Children with Hemophilia A: A Systematic Review

Ceprotin® [Protein C Concentrate (Human)]

  • High-Concentration Protein C Concentrate: In Vitro and In Vivo Feasibility Studies
  • Pharmacokinetics of Protein C in Neonates with Severe Congenital Protein C Deficiency
  • Pharmacokinetics of Protein C Concentrate After Intravenous and Subcutaneous Administration in Göttingen Minipigs

Obizur® [Antihemophilic Factor (Recombinant), Porcine Sequence]

  • Evaluation of Factor VIII Population Pharmacokinetics and Exposure-Response to Support Dosing of Recombinant Porcine Factor VIII in Patients with Acquired Hemophilia A

TAK-330 (4-factor prothrombin complex concentrate [4F-PCC])

  • A Phase 3 Trial of TAK-330 (4-Factor Prothrombin Complex Concentrate [4F-PCC]) vs Standard-Of-Care 4F-PCCs for FXa Inhibitor-Induced Anticoagulation Reversal Before Urgent Surgery/Invasive Procedure

Prothromplex® (Human Prothrombin Complex)

  • Safety Assessment of Prothromplex®, a 4-Factor Prothrombin Complex Concentrate, Focused on Heparin-Related Adverse Events

Professional Society for Health Economics and Outcomes Research (ISPOR), 2024

May 5 - 8, 2024

Leading global conference discussing how to establish, incentivize, and share value sustainable for health systems, patients, and technology developers.

Thrombosis and Hemostasis Societies of North America (THSNA), 2024

April 4 - 6, 2024

A summit of 10 of the leading non-profit organizations in hemostasis and thrombosis, providing expertise and insight on improving patient care.

American Society of Hematology (ASH), 2023

December 9 - 12, 2023

The premier global congress from the world's largest professional society serving both clinicians and scientists working in malignant and classical hematology.

Adynovate® [Antihemophilic Factor (Recombinant), PEGylated] & Advate® [Antihemophilic Factor (Recombinant)]

  • Clinical Outcomes of Noninhibitor Patients with Hemophilia A Switching from Prophylaxis with Factor VIII to Emicizumab: a Meta-analysis of Real-world Evidence Studies
  • Identifying Ideal Individuals for PK-guided Dosing: Recreational Risks and Elevated Breakthrough Bleeding

Vonvendi® [von Willebrand factor (recombinant)]

  • Real-world Use of Recombinant Von Willebrand Factor in People with Clinically Severe Congenital Von Willebrand Disease: Interim Analysis of ATHN 9, A Natural History Study for People with Severe VWD

American Thrombosis and Hemostasis Network Data Summit (ATHN Data Summit), 2023

October 19 - 20, 2023

Annual meeting discussing important research areas of hemophilia, health equity, thrombosis, Von Willebrand disease, rare blood disorders, and data management.

Adynovate® [Antihemophilic Factor (Recombinant), PEGylated] & Advate® [Antihemophilic Factor (Recombinant)]

  • Risk of Intracranial Hemorrhage in US Patients With Hemophilia A: Real-World Retrospective Cohort Study Using the ATHNdataset

Academy of Managed Care Pharmacy Nexus (AMCP Nexus), 2023

October 16 - 19, 2023

Annual event with more than 2,500 members and non-members of the AMCP to engage on the latest innovations and most intentional networking in managed care pharmacy.

Adynovate® [Antihemophilic Factor (Recombinant), PEGylated] & Advate® [Antihemophilic Factor (Recombinant)]

  • Cost Outcomes of Noninhibitor Patients With Hemophilia A Switching From Prophylaxis With Factor VIII to Emicizumab: a Meta-analysis of Real-world Evidence Studies in the United States